Breakthrough at Sheba's Ella Institute for Treatment and Research of Melanoma and Skin Cancer
SHEBA NEWS – August 9, 2015
From: PR Sheba – Ulrike Haen
Sheba researchers have succeeded in isolating an antibody for the treatment of advanced cancer patients.
Prof. Gal Markel and Prof. Jacob Schachter from Sheba Medical Center have succeeded in isolating an antibody that will be used as the basis for treatment of advanced cancer patients with malignancies such as: melanoma, cancer of the lungs, cancer of the urinary bladder, cancer of the stomach, the intestines and the ovaries. The antibody that was developed is based on research that took place in the research laboratories of the Ella (Lemelbaum) Institute for the treatment of melanoma and skin cancer at Sheba.
For the first time in Israel for many years, the scientific development of medication has achieved international recognition and investment, different to other research where international companies invest in medical equipment. This development, due to the huge investment performed at Sheba Medical Center, allows leading researchers with research infrastructure to place emphasis on applied medicine. Alongside the basic scientific development such as immunology, the clinical situation of the patient is put before the researchers' eyes.
"When this kind of research takes place at Sheba Medical Center where patients are hospitalized and solutions have to be found, the scientist accompanies his research all the way from the laboratory to the patient's bed (bench to bed BTB), which is the essence of translational medicine that we are investing in at Sheba. This is an additional step in the integration of the applicatory and scientific ability of Sheba in the pharmaceutical and biotech industry of Israel. We will continue with scientific developments in favor of the sick people in Israel and in the world", said Prof. Shlomo Noy, who is the Vice-President of Research and Development at Sheba.
"My motive is personal, private. It does not arise from the aspiration to complete assignments successfully, but from a willingness to research processes in a way that will lead, in the end, to a genuine impact of reality", added Prof. Gal Markel.
The enormous international medical company "MERCK" has purchased the biomed company cCAM Biotherapeutics, which developed the product together with Sheba Medical Center. This is a significant achievement as well as a vote of confidence in the Israeli innovative biotech industry as a whole.
Prof. Gal Markel Prof. Jacob Schachter